Equities

Ginwa Enterprise Group Inc

600080:SHH

Ginwa Enterprise Group Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)5.72
  • Today's Change-1.15 / -16.74%
  • Shares traded1.15m
  • 1 Year change-26.67%
  • Beta0.8259
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Ginwa Enterprise Group Inc had net income fall from a gain of 33.46m to a loss of 42.89m despite relatively flat revenues.
Gross margin76.18%
Net profit margin-2.67%
Operating margin-3.54%
Return on assets-0.79%
Return on equity-0.97%
Return on investment-0.95%
More ▼

Cash flow in CNYView more

In 2023, Ginwa Enterprise Group Inc increased its cash reserves by 43.24%, or 187.09m. Cash Flow from Investing totalled 137.76m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company generated 60.55m in cash from operations while cash used for financing totalled 11.22m.
Cash flow per share--
Price/Cash flow per share--
Book value per share4.07
Tangible book value per share3.85
More ▼

Balance sheet in CNYView more

Ginwa Enterprise Group Inc has a strong Balance Sheet and has consistently grown its cash reserves over the last Four years to total 619.41m.
Current ratio2.28
Quick ratio2.19
Total debt/total equity0.045
Total debt/total capital0.0431
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items dropped -228.18%.
Div yield(5 year avg)0.34%
Div growth rate (5 year)--
Payout ratio (TTM)--
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-383.79
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.